MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 2127-2133

  Wang, Wei ^a   Ren, Fang ^a   Wu, Qinghua ^a   Jiang, Dazhi ^a   Li, Hongjun ^a,b   Shi, Huirong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

AKT; Angiogenesis; ERK; MicroRNA; MiR 497; Ovarian carcinoma; VEGFA

Indexed keywords

MICRORNA; MICRORNA 497; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; MIRN497 MICRORNA, HUMAN; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CELL; CANCER INHIBITION; CAPILLARY TUBE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN RNA BINDING; TUMOR VASCULARIZATION; AGED; CYSTADENOCARCINOMA; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MICRORNAS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907286869     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3439     Document Type: Article

References (41)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Weis SM and Cheresh DA: Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17: 1359-1370, 2011.
4. Carmeliet P and Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307, 2011.
5. Croce CM: miRNAs in the spotlight: understanding cancer gene dependency. Nat Med 17: 935-936, 2011.
6. Su Y, Li X, Ji W, et al: Small molecule with big role: microRNAs in cancer metastatic microenvironments. Cancer Lett 344: 147-156, 2014.
7. Eilken HM and Adams RH: Turning on the angiogenic microswitch. Nat Med 16: 853-854, 2010.
8. Conteduca V, Kopf B, Burgio SL, Bianchi E, Amadori D and De Giorgi U: The emerging role of anti-Angiogenic therapy in ovarian cancer (Review). Int J Oncol 44: 1417-1424, 2014.
9. Finnerty JR, Wang WX, Hébert SS, Wilfred BR, Mao G and Nelson PT: The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol 402: 491-509, 2010.
10. Flavin RJ, Smyth PC, Laios A, et al: Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Mod Pathol 22: 197-205, 2009.
11. Zhang L, Huang J, Yang N, et al: microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 103: 9136-9141, 2006.
12. Tahiri A, Leivonen SK, Lüders T, et al: Deregulation of cancerrelated miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 35: 76-85, 2014.
13. Creevey L, Ryan J, Harvey H, et al: MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer 12: 23, 2013.
14. Zhao WY, Wang Y, An ZJ, et al: Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer. Biochem Biophys Res Commun 435: 466-471, 2013.
15. Li D, Zhao Y, Liu C, et al: Analysis of miR-195 and miR-497 expression, regulation and role in breast cancer. Clin Cancer Res 17: 1722-1730, 2011.
16. Guo ST, Jiang CC, Wang GP, et al: MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 32: 1910-1920, 2013.
17. Kim YW, Kim EY, Jeon D, et al: Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther 8: 293-314, 2014.
18. Lajer CB, Garnæs E, Friis-Hansen L, et al: The role of miRNAs in human papilloma virus (HPV)-Associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer 106: 1526-1534, 2012.
19. Caramuta S, Lee L, Ozata DM, et al: Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma. Endocr Relat Cancer 20: 551-564, 2013.
20. Lionetti M, Musto P, Di Martino MT, et al: Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res 19: 3130-3142, 2013.
21. Claesson-Welsh L and Welsh M: VEGFA and tumour angiogenesis. J Intern Med 273: 114-127, 2013.
22. Welti J, Loges S, Dimmeler S and Carmeliet P: Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 123: 3190-3200, 2013.
23. Larsen AK, Ouaret D, El Ouadrani K and Petitprez A: Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 131: 80-90, 2011.
24. Anand S and Cheresh DA: Emerging role of micro-RNAs in the regulation of angiogenesis. Genes Cancer 2: 1134-1138, 2011.
25. Zhou B, Ma R, Si W, et al: MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett 333: 159-169, 2013.
26. Sun CY, She XM, Qin Y, et al: miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 34: 426-435, 2013.
27. Zheng X, Chopp M, Lu Y, Buller B and Jiang F: MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Lett 329: 146-154, 2013.
28. Xu Q, Liu LZ, Qian X, et al: MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 40: 761-774, 2012.
29. Zhang H, Pu J, Qi T, et al: MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha. Oncogene 33: 387-397, 2014.
30. Yin R, Bao W, Xing Y, Xi T and Gou S: MiR-19b-1 inhibits angiogenesis by blocking cell cycle progression of endothelial cells. Biochem Biophys Res Commun 417: 771-776, 2012.
31. Saharinen P, Eklund L, Pulkki K, Bono P and Alitalo K: VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 17: 347-362, 2011.
32. Eng L, Azad AK, Habbous S, et al: Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-Analysis. Clin Cancer Res 18: 4526-4537, 2012.
33. Yu L, Deng L, Li J, Zhang Y and Hu L: The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-Analysis. Gynecol Oncol 128: 391-396, 2013.
34. Ferrara N: Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21: 21-26, 2010.
35. Xu Q, Jiang Y, Yin Y, et al: A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IG F-IR and IRS1. J Mol Cell Biol 5: 3-13, 2013.
36. Silva ND Jr, Fernandes T, Soci UP, Monteiro AW, Phillips MI and DE Oliveira EM: Swimming training in rats increases cardiac microRNA-126 expression and angiogenesis. Med Sci Sports Exerc 44: 1453-1462, 2012.
37. Bao L, Yan Y, Xu C, et al: MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett 337: 226-236, 2013.
38. Chan JK, Kiet TK, Blansit K, et al: MiR-378 as a biomarker for response to anti-Angiogenic treatment in ovarian cancer. Gynecol Oncol 133: 568-574, 2014.
39. Pecot CV, Rupaimoole R, Yang D, et al: Tumour angiogenesis regulation by the miR-200 family. Nat Commun 4: 2427, 2013.
40. Vecchione A, Belletti B, Lovat F, et al: A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci USA 110: 9845-9850, 2013.
41. Lai Y, Zhang X, Zhang Z, et al: The microRNA-27a: ZBTB10-specificity protein pathway is involved in follicle stimulating hormone-induced VEGF, Cox2 and survivin expression in ovarian epithelial cancer cells. Int J Oncol 42: 776-784, 2013.